Recent insights into the biology of pancreatic cancer.

EBioMedicine
Wantong YaoHaoqiang Ying

Abstract

Pancreatic cancer (PDAC) is one of the deadliest types of human cancers, owing to late stage at presentation and pervasive therapeutic resistance. The extensive tumour heterogeneity, as well as substantial crosstalk between the neoplastic epithelium and components within the microenvironment are the defining features of PDAC biology that dictate the dismal natural history. Recent advances in genomic and molecular profiling have informed on the genetic makeup and evolutionary patterns of tumour progression, leading to treatment breakthroughs in minor subsets of patients with specific tumour mutational profiles. The nature and function of tumour heterogeneity, including stromal heterogeneity, in PDAC development and therapeutic resistance, are increasingly being elucidated. Deep insight has been gained regarding the metabolic and immunological deregulation, which further sheds light on the complex biology and the observed treatment recalcitrance. Here we will summarize these recent achievements and offer our perspective on the path forward.

Citations

Aug 28, 2020·The Journal of International Medical Research·Adewale Oluwaseun FadakaMervin Meyer
Apr 24, 2020·Nature·Anirban Maitra
Nov 26, 2020·Journal of Cancer Research and Clinical Oncology·Zelin HouHeguang Huang
Jan 23, 2021·Scientific Reports·John KokkinosPhoebe A Phillips
Nov 17, 2020·Case Reports in Oncological Medicine·Hoang Quan NguyenDuc Thanh Hoang
Nov 15, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·M E LorkowskiE Karathanasis
Mar 12, 2021·Journal of Cellular and Molecular Medicine·Stephen J MurphyFerga C Gleeson
May 28, 2021·Expert Opinion on Biological Therapy·Karin Enell SmithPeter Ellmark
May 18, 2021·Indian Journal of Surgical Oncology·Samarth Hegde
Jul 3, 2021·International Journal of Molecular Sciences·Jorge Melendez-Zajgla, Vilma Maldonado
Jun 25, 2021·World Journal of Gastroenterology : WJG·Nikhil Gupta, Raghav Yelamanchi
Jul 3, 2021·Cancers·Sophie C LodestijnMaarten F Bijlsma
Aug 3, 2021·Frontiers in Oncology·Penelope EdwardsIan Chau
Nov 4, 2021·Expert Opinion on Investigational Drugs·Byung Woog Kang, Ian Chau

❮ Previous
Next ❯

Methods Mentioned

BETA
chromosomal aberrations
biopsy
RNAseq
xenograft

Clinical Trials Mentioned

NCT03490669
NCT03520790
NCT02030860
NCT03415854
NCT02758587
NCT02546531
NCT03727880
NCT03331562
NCT03519308

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.